Could the FDA’s first-in-class RAS inhibitor approval mark a turning point in metastatic pancreatic cancer?

This episode highlights FDA approval of the first-in-class RAS inhibitor daraxonrasib for metastatic pancreatic adenocarcinoma, concerning gaps in cervical cancer screening and HPV vaccination among younger women, and new evidence defining which patients may benefit most from coronary artery calcium scoring alongside the PREVENT cardiovascular risk calculator.